Association between Hepatitis B virus infection and COVID-19: outcomes from clinical analysis and online survey from Beijing, China Authors: Fei Lin, Sihan Hao, Xiumei Xiao, Xiaoguang Li Published: 2024 ABSTRACT ObjectiveWe aim to investigate whether Coronavirus disease 2019 (COVID-19) worsens chronic hepatitis B virus(HBV)infection and explore the incidence of long COVID symptoms in patients with chronic hepatitis B virus infection.MethodsPatients with chronic HBV infection and COVID-19 patients attending the hepatitis clinic or fever clinic were included in the study. Clinical manifestations of COVID-19 and information about long COVID were collected for all patients. For patients with chronic hepatitis B virus infection, laboratory test results such as HBV-DNA, liver function, and kidney function were collected three months before and after COVID-19.ResultsA total of 940 patients with COVID-19 were included in this study. These patients were divided into two groups: the hepatitis B virus infection group with 189 patients and the non-hepatitis B group with 751 patients. Further matching analysis was conducted, selecting 156 patients from each group. Within the hepatitis B group, patients were further divided into two subgroups based on whether they received antiviral therapy: 90 patients in the antiviral therapy group and 99 patients in the non-antiviral therapy group. Neither group experienced a significant increase in HBV-DNA after COVID-19. There were significant differences between the two groups regarding BMI and symptoms of sore throat, loss of smell, and nasal congestion during COVID-19. The incidence of long COVID symptoms was higher in the hepatitis B group compared to the non-hepatitis B group (64.1% vs. 48.7%, p < 0.001), with the top five symptoms being cough, fatigue, palpitations, insomnia, and memory impairment.ConclusionPatients with chronic HBV infection did not show a significant rise in HBV DNA after COVID-19 in this study. They had a lower incidence of COVID-19 symptoms but experienced a higher incidence of long COVID symptoms.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-024-10333-z. Introduction Since the outbreak of the novel coronavirus (SARS-CoV-2) at the end of 2019, a global public health crisis has emerged. The acute phase of COVID-19 is characterized by symptoms such as fever, dry cough, sore throat, runny nose, headache and loss of smell and taste. As time progresses, many individuals infected with COVID-19 develop persistent symptoms beyond the acute phase, including chronic cough, fatigue, insomnia, and palpitations, drawing the attention of clinicians [1]. In December 2020, the U.S. National Institutes of Health (NIH) introduced the concept of “long COVID”, defining it as clinical symptoms persisting for 4–12 weeks after the onset of COVID-19. Additionally, the term “post-COVID‐19 syndrome” was defined for patients experiencing symptoms beyond 12 weeks of infection [2]. In 2021, the World Health Organization (WHO) proposed a consensus definition for long COVID, referring to the persistence of clinical symptoms for at least two months after the initial infection, regardless of the severity of the acute phase. This condition is called post‐COVID condition (PCC) [3], with common symptoms including fatigue, cough, generalized pain, or loss of smell and taste [4]. Studies have reported varying prevalence rates of long COVID. A Danish study revealed that 12.7% of COVID-19 patients experienced prolonged symptoms [5], another study from Scotland found a high prevalence of long COVID, reaching up to 62% [6]. In December 2022, China abolished the restrictions for COVID-19, leading to a widespread surge in COVID-19. Large-scale surveys indicated an estimated COVID-19 infection rate of 83.6% in the general population [7]. China also has the largest population of hepatitis B virus (HBV) infection, with approximately 87 million people with chronic HBV infection, accounting for one-third of the total global HBV infection [8]. Given that SARS-CoV-2 can infect liver cells, it is elusive whether SARS-CoV-2 could impact liver diseases, e.g., chronic hepatitis B. Currently, there is no clear conclusion regarding the relationship between HBV infection and COVID-19. A meta-analysis showed that HBV infection did not worsen or prolong hospitalization for COVID-19 [9]. A nationwide study based on the health insurance system found that HBV infection did not affect the clinical outcomes of COVID-19 [10]. However, another meta-analysis suggested that co-infection with HBV could lead to a higher mortality and severity rate in COVID-19, with a higher incidence of abnormal liver function as well [11]. Thus, there is considerable interest in studying the clinical characteristics of individuals with COVID-19 and HBV infection. It is also essential to investigate the impact of COVID-19 on chronic hepatitis B and the influence of hepatitis B infection on COVID-19. Our research revealed that HBV-DNA in patients with chronic HBV infection did not rise after COVID-19. However, chronic HBV infected patients have a higher incidence of long COVID symptoms compared to the general population. Methods Study design Study Population: Patients who visited the fever clinic or hepatitis clinic at Peking University Third Hospital between January 1, 2023 and June 6, 2023. Study Methods: Cross-sectional survey with both questionnaire surveys and case data recording. The questionnaire was developed for this study (see as the supplementary file). Inclusion Criteria: Participants must be willing to take questionnaire surveys and sign informed consent forms. Patients with chronic hepatitis B virus infection must meet the diagnostic criteria outlined by the American Association for the Study of Liver Diseases (AASLD) in 2018 [12]. Exclusion Criteria: Patients with chronic HBV infection must be excluded if they have concurrent infections with other hepatitis viruses, human immunodeficiency virus, or conditions that may lead to liver damage, such as autoimmune hepatitis, alcoholic hepatitis, non-alcoholic fatty liver disease, drug-induced liver injury, etc. The non-hepatitis B virus infection group must exclude HBV infection. Sample Size and Groups: 1,012 people accepted the survey, and 947 valid responses were collected. Among them were 191 hepatitis B patients, 756 non-hepatitis B patients, 945 with COVID-19, and two without COVID-19. After excluding incomplete data from 5 individuals, 940 participants were included in this study, all of whom were COVID-19. They were divided into two groups: the hepatitis B group, with 189 patients, and the non-hepatitis B group, with 751 patients. Further matched analysis was conducted with 156 cases selected from each group. Data Collection: Demographic information, medical history (including history of hepatitis B infection), COVID-19 status, and COVID-19 vaccination status (defined as receiving two doses of COVID-19 vaccine according to the vaccination plan or, in addition to the two doses, receiving a third or fourth booster dose) were collected. Clinical manifestations were recorded, including short-term symptoms during COVID-19 and long-term symptoms (lasting more than four weeks) after infection. Laboratory tests included hepatitis B-related indicators for the three months before and after COVID-19 (HBV-DNA, quantitative HBsAg, liver function, renal function, etc., with specific normal value ranges and units provided for each test). HBV DNA level was tested using Roche’s COBAS TaqMan kit following the manufacturer’s instruction (Roche Diagnostics, Pleasanton, CA, USA). The undetectable level was 10 IU/ml. Serum levels of HBeAg and HBsAg were quantitatively assessed using Abbott Architect assays (Abbott Diagnostics; Abbott Park, IL, USA). Liver and kidney function and other biochemical parameters were examined by an automatic biochemical analyzer at the Clinical Laboratory of Peking University 3rd Hospital. Statistical Methods: Descriptive analysis was performed for intra-group data, using a median for quantitative data and rates for qualitative data. Propensity score matching analysis was performed to match patients in a 1:1 ratio based on age and gender. Inter-group comparisons used independent sample t-tests for quantitative data (e.g., age, BMI) and paired sample t-tests for hepatitis B patients’ laboratory test results before and after COVID-19. Qualitative data were analyzed using chi-square tests. All calculations were performed using SPSS version 26.0 Win32 (SPSS Inc, Chicago, IL, USA), and a significance level of P < 0.05 was considered statistically significant. Ethical approval This study obtained approval from the Medical Science Research Ethics Committee of Peking University Third Hospital, with the ethical approval number being (2023) Medical Ethics Review No. (094 − 01) and the project number IRB0000676-M2023087. Results Demographic and epidemiological characteristics The patients’ ages ranged from 18 to 90 years, and the number of patients was 940. There were 510 male patients (54.2%) and 430 female patients (45.7%). In the hepatitis B group (189 patients), there were 111 males (58.7%) and 78 females (41.3%), while in the non-hepatitis B group (751 patients), there were 397 males (52.9%) and 354 females (47.1%). There was no significant difference in gender distribution (p > 0.05). Regarding age distribution, in the hepatitis B group, there were 107 individuals aged 18–44 years old, 61 aged 45–64, and 21 aged 65 and above. In the non-hepatitis B group, 691 individuals were aged 18–44, 51 were aged 45–64, and 9 were aged 65 and above. There was a significant difference in age distribution between the two groups (p < 0.001). Laboratory tests before and after COVID-19 in Hepatitis B patients In the hepatitis B group (189 patients), further subgroups were formed based on antiviral therapy. Ninety patients received antiviral treatment, with 46 using entecavir (ETV), 34 using tenofovir alafenamide fumarate (TAF), and 6 using tenofovir disoproxil fumarate (TDF). Ninety-nine patients did not receive antiviral treatment. Laboratory test comparisons within the three months before and after COVID-19 are presented in Table 1. Table 1Comparison of laboratory test results before and after COVID-19 in 189 Hepatitis B patientsbefore COVID-19 (antiviral group)after COVID-19 (antiviral group)pairedtp valuebefore COVID-19 (non-antiviral group)after COVID-19 (non-antiviral group)paired tp valuenumber90909999HBsAg474680491.0790.28667375079-1.6520.108HBVDNA50,3861992-1.4010.1682.942*1071.389*107-1.160.254Log10 HBVDNA1.61.0-2.7390.0113.93.6-1.1750.261ALT(IU/L)31.335.20.5710.5736.531.3-1.1710.247AST(IU/L)29.130.00.2890.77333.130.5-0.7020.486TBil(µmol/L)18.117.2-1.8910.06316.516.0-0.8770.385ALP(IU/L)71.274.32.3470.02275.880.82.3450.024γ-GT(IU/L)29.227.2-0.8130.41930.931.30.2430.809Cr(µmol/L)82.778.3-4.703< 0.00180.078.8-1.1570.254β2-mg2.12.0-0.2790.7821.81.91.140.268eGFR(ml/min)90.995.64.537< 0.00193.994.70.6160.541CK(IU/L)247.8117.9-1.1880.241186.4120.4-2.0780.05U-NAG(IU/L)4.85.60.5410.65.62.9N/AN/AU-RBP(mg/L)0.30.3-0.8590.4130.30.3N/AN/AHBsAg: Hepatitis B surface antigen, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, TBil: Total Bilirubin, ALP: Alkaline Phosphatase, γ-GT: Gamma-glutamyl transferase, Cr: creatinine, β2-mg: β2-microglobulin, eGFR: estimated glomerular filtration rate, CK: Creatine Kinase, U-NAG: urinary N-acetyl-β-D- glucosaminidase, U-RBP: urinary retinol-binding protein Table 1Comparison of laboratory test results before and after COVID-19 in 189 Hepatitis B patientsbefore COVID-19 (antiviral group)after COVID-19 (antiviral group)pairedtp valuebefore COVID-19 (non-antiviral group)after COVID-19 (non-antiviral group)paired tp valuenumber90909999HBsAg474680491.0790.28667375079-1.6520.108HBVDNA50,3861992-1.4010.1682.942*1071.389*107-1.160.254Log10 HBVDNA1.61.0-2.7390.0113.93.6-1.1750.261ALT(IU/L)31.335.20.5710.5736.531.3-1.1710.247AST(IU/L)29.130.00.2890.77333.130.5-0.7020.486TBil(µmol/L)18.117.2-1.8910.06316.516.0-0.8770.385ALP(IU/L)71.274.32.3470.02275.880.82.3450.024γ-GT(IU/L)29.227.2-0.8130.41930.931.30.2430.809Cr(µmol/L)82.778.3-4.703< 0.00180.078.8-1.1570.254β2-mg2.12.0-0.2790.7821.81.91.140.268eGFR(ml/min)90.995.64.537< 0.00193.994.70.6160.541CK(IU/L)247.8117.9-1.1880.241186.4120.4-2.0780.05U-NAG(IU/L)4.85.60.5410.65.62.9N/AN/AU-RBP(mg/L)0.30.3-0.8590.4130.30.3N/AN/AHBsAg: Hepatitis B surface antigen, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, TBil: Total Bilirubin, ALP: Alkaline Phosphatase, γ-GT: Gamma-glutamyl transferase, Cr: creatinine, β2-mg: β2-microglobulin, eGFR: estimated glomerular filtration rate, CK: Creatine Kinase, U-NAG: urinary N-acetyl-β-D- glucosaminidase, U-RBP: urinary retinol-binding protein Comparison of laboratory test results before and after COVID-19 in 189 Hepatitis B patients HBsAg: Hepatitis B surface antigen, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, TBil: Total Bilirubin, ALP: Alkaline Phosphatase, γ-GT: Gamma-glutamyl transferase, Cr: creatinine, β2-mg: β2-microglobulin, eGFR: estimated glomerular filtration rate, CK: Creatine Kinase, U-NAG: urinary N-acetyl-β-D- glucosaminidase, U-RBP: urinary retinol-binding protein The average HBV DNA viral load decreased from 50,386 to 1,992 IU/ml, and log10 HBV DNA decreased from 1.64 to 1.01 in the antiviral group, showing significant differences (p = 0.011). There was no significant difference in HBV DNA before and after COVID-19 (p > 0.05) in the non-antiviral group. For liver function, alkaline phosphatase (ALP) levels for those receiving antiviral treatment were 71.2 before and 74.3 after COVID-19, while for those without antiviral treatment, they were 75.8 before and 80.8 after, both showing significant differences (p < 0.05). No significant differences were observed in other indicators, including ALT, AST, TBil, and γ-GT before and after COVID-19. As for kidney function, mean creatinine (Cr) levels for those receiving antiviral treatment were 82.7 before and 78.3 after COVID-19, showing significant differences (p < 0.001). For those without antiviral treatment, there was no significant difference in Cr levels. Estimated glomerular filtration rate (eGFR) levels for those receiving antiviral treatment were 90.9 before and 95.6 after COVID-19, showing significant differences (p < 0.001). For those without antiviral treatment, there was no significant difference in eGFR levels (p = 0.541). Propensity score matching analysis of COVID-19 symptoms between Hepatitis B and Non-Hepatitis B Groups Among COVID-19 patients, there were 508 males (54.0%) and 432 females (46.0%). Notably, in patients with long COVID, there was a significant difference in gender distribution with 215 males (42.3%) and 237 females (54.9%). Regarding age distribution, among long COVID patients, there were 380 individuals aged 18–44, 60 aged 45–64, and 12 aged 65 and above. In contrast, among those without long COVID, 418 individuals aged below 44, 52 aged 45–64, and 18 aged 65 and above. The age distribution also exhibited significant differences. After conducting a propensity score matching analysis, patients were matched in a 1:1 ratio based on age and gender. With 156 cases in both the Hepatitis B and non-hepatitis B groups, a comparison was performed (see Table 2). Table 2Propensity score matching analysis of clinical manifestations in Hepatitis B and non-hepatitis B patients with COVID-19hepatitis B patients (n=156)non-hepatitis B patients (n=156)p-valuevaccination status, N (%)130(83.3)117(75.0)0.032acute phase of COVID-190.087- 1-3 days, N (%)32(20.5)25(16.0)- 4-5 days, N (%)35(22.4)32(20.5)- 6-7 days, N (%)40(25.6)51(32.7)- >7 days, N (%)24(15.4)17(10.9)covid-19 symptoms- fever, N (%)132(84.6)108(69.2)0.760- dry cough, N (%)72(46.2)66(42.3)0.457- fatigue, N (%)79(50.6)78(50.0)0.072- sore throat, N (%)74(47.4)79(50.6)0.016- reduced sense of smell, N (%)23(14.7)31(19.9)0.037- reduced sense of taste, N (%)27(17.3)30(19.2)0.174- nasal congestion, N (%)42(26.9)56(35.9)0.003- runny nose, N (%)46(29.5)49(31.4)0.100- conjunctivitis, N (%)4(2.6)1(0.6)0.267- muscle pain, N (%)55(35.2)49(31.4)0.514- diarrhea, N (%)58(37.2)58(37.2)0.139- headache, N (%)9(5.8)11(7.0)0.329- other symptoms, N (%)7(4.5)3(1.9)0.315long COVID symptoms, N (%)100(64.1)76(48.7)<0.001- cough, N (%)68(43.6)52(33.3)0.483- shortness of breath, N (%)5(3.2)6(3.8)0.557- chest pain, N (%)7(4.5)5(3.2)0.766- palpitations, N (%)20(12.8)11(7.0)0.222- fatigue, N (%)35(22.4)21(13.5)0.167- insomnia, N (%)17(10.9)10(6.4)0.336- reduced memory, N (%)12(7.7)4(2.6)0.086- diarrhea, N (%)5(3.2)1(0.6)0.147- appetite loss, N (%)9(5.8)7(4.5)0.861- hair loss, N (%)3(1.9)1(0.6)0.399- rash, N (%)1(0.6)4(2.6)0.123- headache, N (%)7(4.5)3(1.9)0.306- other, N (%)4(2.6)1(0.6)0.242subjective health assessment0.274- better than before, N (%)5(3.2)11(7.0)- no change, N (%)79(50.6)67(42.9)- worse than before, N (%)56(35.9)42(26.9)- much worse than before, N (%)10(6.4)7(4.5)BMI composition<0.001- BMI <18.5, N (%)3(1.9)17(10.9)- BMI 18.5-25, N (%)99(63.5)105(67.3)- BMI 25-30, N (%)42(26.9)28(17.9)- BMI >30, N (%)12(7.7)6(3.8)BMI: Body Mass Index Table 2Propensity score matching analysis of clinical manifestations in Hepatitis B and non-hepatitis B patients with COVID-19hepatitis B patients (n=156)non-hepatitis B patients (n=156)p-valuevaccination status, N (%)130(83.3)117(75.0)0.032acute phase of COVID-190.087- 1-3 days, N (%)32(20.5)25(16.0)- 4-5 days, N (%)35(22.4)32(20.5)- 6-7 days, N (%)40(25.6)51(32.7)- >7 days, N (%)24(15.4)17(10.9)covid-19 symptoms- fever, N (%)132(84.6)108(69.2)0.760- dry cough, N (%)72(46.2)66(42.3)0.457- fatigue, N (%)79(50.6)78(50.0)0.072- sore throat, N (%)74(47.4)79(50.6)0.016- reduced sense of smell, N (%)23(14.7)31(19.9)0.037- reduced sense of taste, N (%)27(17.3)30(19.2)0.174- nasal congestion, N (%)42(26.9)56(35.9)0.003- runny nose, N (%)46(29.5)49(31.4)0.100- conjunctivitis, N (%)4(2.6)1(0.6)0.267- muscle pain, N (%)55(35.2)49(31.4)0.514- diarrhea, N (%)58(37.2)58(37.2)0.139- headache, N (%)9(5.8)11(7.0)0.329- other symptoms, N (%)7(4.5)3(1.9)0.315long COVID symptoms, N (%)100(64.1)76(48.7)<0.001- cough, N (%)68(43.6)52(33.3)0.483- shortness of breath, N (%)5(3.2)6(3.8)0.557- chest pain, N (%)7(4.5)5(3.2)0.766- palpitations, N (%)20(12.8)11(7.0)0.222- fatigue, N (%)35(22.4)21(13.5)0.167- insomnia, N (%)17(10.9)10(6.4)0.336- reduced memory, N (%)12(7.7)4(2.6)0.086- diarrhea, N (%)5(3.2)1(0.6)0.147- appetite loss, N (%)9(5.8)7(4.5)0.861- hair loss, N (%)3(1.9)1(0.6)0.399- rash, N (%)1(0.6)4(2.6)0.123- headache, N (%)7(4.5)3(1.9)0.306- other, N (%)4(2.6)1(0.6)0.242subjective health assessment0.274- better than before, N (%)5(3.2)11(7.0)- no change, N (%)79(50.6)67(42.9)- worse than before, N (%)56(35.9)42(26.9)- much worse than before, N (%)10(6.4)7(4.5)BMI composition<0.001- BMI <18.5, N (%)3(1.9)17(10.9)- BMI 18.5-25, N (%)99(63.5)105(67.3)- BMI 25-30, N (%)42(26.9)28(17.9)- BMI >30, N (%)12(7.7)6(3.8)BMI: Body Mass Index Propensity score matching analysis of clinical manifestations in Hepatitis B and non-hepatitis B patients with COVID-19 BMI: Body Mass Index The composition of BMI categories showed significant differences between the two groups. In the Hepatitis B group, the proportions for BMI categories (< 18.5, 18.5–25, 25–30, > 30) were 1.9%, 63.5%, 26.9%, and 7.7%, respectively. The corresponding proportions in the non-Hepatitis B group were 10.9%, 67.3%, 17.9%, and 3.8%, indicating statistically significant differences (p < 0.001). Vaccine coverage also showed a significant difference, with complete vaccination rates of 83.3% in the Hepatitis B group and 75.0% in the non-Hepatitis B group (p = 0.032). Analysis of COVID-19 symptoms revealed that the top four symptoms, with incidence rates exceeding 40%, were fever, dry cough, fatigue, and sore throat. The second-largest group, with 20–40% incidence rates, included symptoms such as nasal congestion, runny nose, muscle pain, and diarrhea. Other symptoms forming the third-largest group with incidence rates below 20% include loss of taste, loss of smell, headache, and conjunctivitis. In the analysis of long COVID symptoms, 100 cases (64.1%) were observed among Hepatitis B group compared to 76 cases (48.7%) of the non-Hepatitis B group, showing a significant difference (p < 0.001). The primary long COVID symptoms were cough (43.6%), fatigue (22.4%), palpitations (12.8%), insomnia (10.9%), and reduced memory (7.7%). Regarding the duration of symptoms lasting more than seven days, the percentage was 15.4% in the Hepatitis B group and 10.9% in the non-Hepatitis B group. Subjective health assessments for long COVID indicated that 35.9% in the Hepatitis B group felt worse than before, while 6.4% felt much worse. These percentages were 26.9% and 4.5% in the non-Hepatitis B group. Analysis of COVID-19 symptoms in Hepatitis B patients between antiviral subgroup and Non-antiviral subgroup We also conducted a comparative analysis of COVID-19 symptoms in the antiviral treatment subgroup and the non-antiviral treatment subgroup within the hepatitis B group (see Table 3). Table 3Analysis of COVID-19 Clinical Manifestations in Hepatitis B patients of antiviral group and non-antiviral groupNon-antiviral group (n=99)Antiviral group (n=90)p-valuevaccination status, N (%)86(86.9)77(85.6)0.794acute phase of COVID-190.051- 1-3 days, N (%)15(15.3)27(31.4)- 4-5 days, N (%)20(20.4)19(22.1)- 6-7 days, N (%)30(30.6)15(17.4)- >7 days, N (%)19(19.4)17(19.8)COVID-19 symptoms85(85.9)79(87.8)0.697- fever, N (%)69(70.4)68(79.1)0.179- dry cough, N (%)48(49.0)31(36.0)0.077- fatigue, N (%)40(40.8)31(36.0)0.507- sore throat, N (%)46(46.9)25(29.1)0.013- reduced sense of smell, N (%)10(10.2)4(4.7)0.156- reduced sense of taste, N (%)13(13.3)7(8.1)0.265- nasal congestion, N (%)23(23.5)12(14.0)0.101- runny nose, N (%)21(21.4)15(17.4)0.496- conjunctivitis, N (%)3(3.1)0(0)0.102- muscle pain, N (%)25(25.5)26(30.2)0.475- diarrhea, N (%)5(5.1)3(3.5)0.592- headache, N (%)32(32.7)17(19.8)0.049- other symptoms, N (%)3(3.0)3(3.3)0.906long COVID symptoms, N (%)56(56.6)38(42.2)0.049- cough, N (%)42(42.4)22(24.4)0.009- shortness of breath, N (%)3(3.0)1(1.1)0.360- chest pain, N (%)5(5.1)1(1.1)0.123- palpitations, N (%)12(12.1)8(8.9)0.471- fatigue, N (%)16(16.2)14(15.6)0.909- insomnia, N (%)10(10.1)6(6.7)0.397- reduced memory, N (%)7(7.1)4(4.4)0.441- diarrhea, N (%)4(4.0)0(0)0.054- appetite loss, N (%)7(7.1)2(2.2)0.118- hair loss, N (%)1(1.0)2(2.2)0.505- rash, N (%)1(1.0)1(1.1)0.946- headache, N (%)3(3.0)4(4.4)0.607- other, N (%)1(1.0)2(2.2)0.505subjective health assessment0.056- better than before, N (%)3(3.0)2(2.2)- no change, N (%)38(38.4)38(42.2)- worse than before, N (%)35(35.4)16(17.8)- much worse than before, N (%)3(3.0)6(6.7)BMI composition0.206- BMI <18.5, N (%)3(3.0)1(1.1)- BMI 18.5-25, N (%)64(64.6)54(60)- BMI 25-30, N (%)20(20.2)28(31.1)- BMI >30, N (%)9(9.1)3(3.3)BMI: Body Mass Index Table 3Analysis of COVID-19 Clinical Manifestations in Hepatitis B patients of antiviral group and non-antiviral groupNon-antiviral group (n=99)Antiviral group (n=90)p-valuevaccination status, N (%)86(86.9)77(85.6)0.794acute phase of COVID-190.051- 1-3 days, N (%)15(15.3)27(31.4)- 4-5 days, N (%)20(20.4)19(22.1)- 6-7 days, N (%)30(30.6)15(17.4)- >7 days, N (%)19(19.4)17(19.8)COVID-19 symptoms85(85.9)79(87.8)0.697- fever, N (%)69(70.4)68(79.1)0.179- dry cough, N (%)48(49.0)31(36.0)0.077- fatigue, N (%)40(40.8)31(36.0)0.507- sore throat, N (%)46(46.9)25(29.1)0.013- reduced sense of smell, N (%)10(10.2)4(4.7)0.156- reduced sense of taste, N (%)13(13.3)7(8.1)0.265- nasal congestion, N (%)23(23.5)12(14.0)0.101- runny nose, N (%)21(21.4)15(17.4)0.496- conjunctivitis, N (%)3(3.1)0(0)0.102- muscle pain, N (%)25(25.5)26(30.2)0.475- diarrhea, N (%)5(5.1)3(3.5)0.592- headache, N (%)32(32.7)17(19.8)0.049- other symptoms, N (%)3(3.0)3(3.3)0.906long COVID symptoms, N (%)56(56.6)38(42.2)0.049- cough, N (%)42(42.4)22(24.4)0.009- shortness of breath, N (%)3(3.0)1(1.1)0.360- chest pain, N (%)5(5.1)1(1.1)0.123- palpitations, N (%)12(12.1)8(8.9)0.471- fatigue, N (%)16(16.2)14(15.6)0.909- insomnia, N (%)10(10.1)6(6.7)0.397- reduced memory, N (%)7(7.1)4(4.4)0.441- diarrhea, N (%)4(4.0)0(0)0.054- appetite loss, N (%)7(7.1)2(2.2)0.118- hair loss, N (%)1(1.0)2(2.2)0.505- rash, N (%)1(1.0)1(1.1)0.946- headache, N (%)3(3.0)4(4.4)0.607- other, N (%)1(1.0)2(2.2)0.505subjective health assessment0.056- better than before, N (%)3(3.0)2(2.2)- no change, N (%)38(38.4)38(42.2)- worse than before, N (%)35(35.4)16(17.8)- much worse than before, N (%)3(3.0)6(6.7)BMI composition0.206- BMI <18.5, N (%)3(3.0)1(1.1)- BMI 18.5-25, N (%)64(64.6)54(60)- BMI 25-30, N (%)20(20.2)28(31.1)- BMI >30, N (%)9(9.1)3(3.3)BMI: Body Mass Index Analysis of COVID-19 Clinical Manifestations in Hepatitis B patients of antiviral group and non-antiviral group BMI: Body Mass Index Among the COVID-19 symptoms, the incidences of sore throat and headache were lower in the antiviral treatment subgroup compared to the non-antiviral treatment subgroup, which were (46.9% vs. 29.1%, p = 0.013) and (32.7% vs. 19.8%, p = 0.049), respectively. There were no statistically significant differences in other symptoms between the two groups. Regarding the incidence of long COVID symptoms, the incidence rate in the antiviral treatment subgroup was lower than that in the non-antiviral treatment subgroup (42.2% vs. 56.6%, p = 0.049). As for the incidence of dry cough among long COVID symptoms, the antiviral treatment subgroup again had a lower incidence rate compared to the non-antiviral treatment subgroup (24.4% vs. 42.4%, p = 0.009). Discussion This study comprehensively investigated the clinical characteristics of COVID-19 in patients with hepatitis B. The average HBVDNA of chronic Hepatitis B patients didn’t rise after COVID-19. Biochemical markers revealed an elevation in ALP, a decrease in blood creatinine levels, and an increase in eGFR after COVID-19. Significant differences were observed between the two groups regarding BMI and specific COVID-19 symptoms. Long COVID symptoms were found to be more prevalent in the hepatitis B group compared to the non-hepatitis B group. We intend to explore whether COVID-19 affects the condition of HBV infection. A comparative analysis of clinical data before and after COVID-19 in hepatitis B patients was conducted, focusing on whether there is a reactivation of the HBV after COVID-19. The results revealed that in the group receiving antiviral treatment for hepatitis B, the HBV DNA levels before and after COVID-19 were 5.0 × 104 IU/ml and 2.0 × 103 IU/ml, respectively, showing a significant difference after conversion to log10 HBVDNA. In the untreated hepatitis B group, the HBVDNA levels before and after COVID-19 were 2.9 × 107 IU/ml and 1.4 × 107 IU/ml, respectively, with no significant difference. Further analysis, considering the potential impact of antiviral treatment on the decline in HBV levels, indicated that COVID-19 did not significantly affect HBV levels in this study. No evidence was found in this study to suggest a significant increase in HBV viral load after COVID-19. However, we indeed observed increase in HBV DNA levels in six patients, but none of them exhibited abnormal liver function. Among these, two patients in the antiviral subgroup experienced an increase in HBV DNA levels: one patient using TAF, HBVDNA changing from 4.32 × 102 IU/ml to 5.3 × 102 IU/ml, and one patient using TDF, HBVDNA changing from 1.15 × 102 IU/ml to 3.13 × 103 IU/ml. Whether the increase in HBV DNA levels in these two patients is directly related to COVID-19 infection remains uncertain. It is necessary to consider the possibility of poor antiviral treatment efficacy leading to low-level fluctuations or increase in HBVDNA. In the non-antiviral treatment subgroup, four patients experienced an increase in HBV DNA levels: from 4.42 × 103 IU/ml to 6.83 × 103 IU/ml, from < 10 IU/ml to 18.1 IU/ml, from 1.39 × 104 IU/ml to 1.98 × 104 IU/ml, and from 5.42 × 104 IU/ml to 1.6 × 105 IU/ml, respectively. The increase in HBV DNA levels in these patients cannot be definitively attributed to COVID-19 infection, as the fluctuations are generally within the same scale. For HBV carriers, such fluctuations are very common. The definition of HBV reactivation generally refers to an increase in HBV DNA levels by ≥ 2 log from the baseline level [13]. Based on this definition, those 6 patients did not meet the criteria for HBV reactivation. However, there are conflicting reports on whether COVID-19 can lead to the reactivation of the HBV. For instance, in a study by Liu et al., among 19 hospitalized patients with concurrent HBV infection and COVID-19, three cases experienced a reactivation of HBV. Two of them received corticosteroid treatment during hospitalization, while one did not. In one case, the HBV DNA level increased from undetectable to 3.79 log10 [14]. Librero-Jimenez M et al. reported a case of a hepatitis B cirrhosis patient treated with tenofovir who experienced HBV reactivation after COVID-19, ultimately leading to liver failure and death, and COVID-19 was attributed to the reactivation of HBV [15].In a study by Rentao Yu et al., seven COVID-19 patients with HBV infection showed no significant differences between admission and discharge [16]. Our results are generally consistent with these findings, as we did not observe a significant increase in HBV DNA in HBV-infected individuals after COVID-19. However, whether COVID-19 can definitively lead to HBV reactivation requires further research. In this study, the biochemical indicators of patients receiving antiviral treatment showed improvements in blood creatinine and eGFR compared to before the COVID-19. At the same time, ALP increased, but all these changes remained within the normal range. In comparison to other studies on COVID-19 and liver injury, Ming Wang et al.’s research showed liver damage in 46.1% (303 out of 657) of hospitalized COVID-19 patients [17]. Meaghan M. Phipps et al. found that among 2273 COVID-19 patients, 45% had mild liver damage (ALT < 2ULN), and 21% had moderate liver damage (2ULN < ALT < 5ULN) [18]. Xiaojing Zou et al.’s study indicated that out of 105 COVID-19 patients with concurrent HBV infection, 14 cases experienced liver injury, with 10 patients (13.33%) recovering rapidly, while 4 cases developed subacute liver failure [19]. These studies suggest that a certain proportion of patients experience acute liver injury during the acute phase of COVID-19. In contrast, our study revealed no significant abnormalities in liver function among patients in the HBV group after COVID-19, indicating that the SARS-CoV-2 infection may not result in persistent liver damage. For the relationship of COVID-19 and renal function, a meta-analysis conducted by Setor K. Kunutsor et al., including 22 studies with a total of 17,931 COVID-19 patients hospitalized for 2–28 days, revealed that 11% of patients experienced acute kidney injury (AKI) [20]. Another meta-analysis by Samuel A. Silver et al., comprising 54 studies with 30,639 COVID-19 patients, reported an overall incidence of acute kidney injury at 28%, with 8% of patients requiring renal replacement therapy [21]. These studies suggest a high incidence of acute kidney injury during the acute phase of COVID-19. In a study by Muhammed Bekçibaşı et al., which included 20 COVID-19 patients with concurrent HBV infection and 136 COVID-19 patients without HBV infection, those without concurrent HBV infection had significantly higher creatinine levels, and the incidence of severe cases was lower in those with concurrent HBV infection [22]. Our study showed that patients receiving antiviral treatment had improved renal function indicators, including creatinine and eGFR, after COVID-19. This result suggests that mild COVID-19 may not significantly impact the renal function of HBV patients. Additionally, 40% (34/90) of those receiving antiviral treatment were treated with tenofovir alafenamide, which has renal protective effects and may improve renal function before and after treatment. We also explored whether HBV infection influences the symptoms of COVID-19. After conducting a matching analysis for gender and age between the HBV group and the non-HBV group, we found that the incidence rates of sore throat, anosmia, and nasal congestion symptoms were lower in the HBV group. In a study by Jian Wu et al., a comparison of clinical characteristics between 70 COVID-19 patients with concurrent HBV infection and 550 COVID-19 patients without HBV infection showed no significant differences in the time for COVID-19 nucleic acid to turn negative and the length of hospital stay. However, the average ALT, AST, and activated partial thromboplastin time (APTT) levels were higher in the HBV group, with 36 cases (51.43%) showing abnormal ALT and AST levels [23]. It is noteworthy that the overweight population in the hepatitis B group is larger than in the non-hepatitis B group. Overweight individuals often have abnormalities in blood lipids and fatty liver disease. Various studies have reported that the incidence of fatty liver disease in individuals with chronic hepatitis B can be as high as 47.9% [24, 25]. A study by Xu Gao et al. during the COVID-19 pandemic showed a significant increase in mortality among individuals with alcoholic liver disease and non-alcoholic fatty liver disease. However, there was no significant increase in mortality among patients with chronic hepatitis B [26]. Combining our research findings, although the proportion of overweight individuals is higher in the hepatitis B group compared to the non-hepatitis B group, the incidence of COVID-19 symptoms in the hepatitis B group remains lower. This result may suggest that the hepatitis B virus infection itself does not exacerbate the COVID-19. Following the global outbreak of COVID-19, long COVID has gradually become a focus of attention for clinicians and the general public.One study by Hui Zhang et al. investigated the health status of COVID-19 hospitalized patients in the early stages of the pandemic. The research revealed that two years after COVID-19, 55% of patients had long COVID, and 54% had at least one lingering symptom from COVID-19 [27]. Our study found that the prevalence of long COVID symptoms in the hepatitis B group was higher than in the non-hepatitis B group. The top 5 symptoms in descending order were cough, fatigue, palpitations, insomnia, and memory decline. Considering that these symptoms are mostly subjectively assessed and cannot be measured by objective standards, individuals with chronic diseases like hepatitis B may have a high sensitivity to symptoms due to fluctuations in their physical and mental states. Studies by Rajesh Gupta and others showed a significant presence of mental health issues in hepatitis B patients, with a substantial percentage meeting diagnostic criteria for at least one mental health disorder [28]. Furthermore, Cichun W et al.’s research indicated that 30% of hepatitis B patients experienced sleep disorders [29]. These studies highlight the importance of addressing mental health issues in hepatitis B patients, as negative feedback may be more likely to appear in subjective assessments of their health status. On the other hand, chronic hepatitis B patients generally have a weakened immune status because many complexed factors contribute to their immune compression. For instance, HBV proteins can disturb the cellular production of antiviral cytokines like type I IFNs, HBV antigens such as HBsAg and HBeAg could suppress Toll-like receptor (TLR)-induced immune responses [30]. It remains unclear whether this is related to a higher incidence of long COVID symptoms. In the analysis of COVID-19 symptoms between the antiviral treatment and non-antiviral treatment subgroups of hepatitis B patients, we found that the incidence of sore throat and headache was lower in the antiviral treatment group compared to the non-antiviral treatment group. Moreover, the overall incidence of long COVID symptoms and dry cough was also lower in the antiviral treatment group. This suggests that antiviral treatment for hepatitis B might have a certain inhibitory effect on COVID-19 infection and the occurrence of long COVID symptoms. Research has shown that compared to entecavir (ETV), tenofovir disoproxil fumarate (TDF) can reduce the severity of COVID-19 infection in hepatitis B patients [31]. Furthermore, tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) has been demonstrated to lower the infection rate and hospitalization rate due to COVID-19 among HIV-infected individuals [32]. Molecular studies indicate that TDF and similar nucleotide analogs can inhibit the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 [33]. However, one in vitro study has shown that TDF does not exhibit activity against SARS-CoV-2 [34]. Therefore, whether hepatitis B antiviral drugs such as TDF possess definitive anti-SARS-CoV-2 activity requires further investigation. This study has some limitations. Firstly, the included patients were all outpatients, representing only mild cases of COVID-19 and may not reflect the clinical manifestations of moderate to severe cases. Secondly, the lack of clinical data during the acute phase of COVID-19 hinders a more precise analysis of patient recovery. Future studies should include more moderate to severe COVID-19 cases with HBV infection to obtain more convincing conclusions. In conclusion, our study revealed that individuals in the hepatitis B group did not show a significant increase in HBV DNA after COVID-19. Compared to the non-hepatitis B group, individuals in the hepatitis B group had lower incidence rates of symptoms such as sore throat, diminished sense of smell, and nasal congestion. However, they had a higher incidence of long COVID symptoms. We should pay more attention to long COVID symptoms in individuals with hepatitis B. Furthermore, longer-term follow-up is required to observe changes in long COVID symptoms in this population. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1